• Unsere Werte verbinden

Originalarbeiten

  1. Dohmen B, Loos U (1990) Chemilumineszenz von Alveolarmakrophagen bei Pneumonie. Pneumologie 44 Suppl 1, 467-8.
  2. Biedermann M, Bares R, Grün B, Dohmen BM, Sabri O, Friedberg C, Büll U (1995) KST und Onkoszintigraphie mit 99mTc-MIBI in der Nachsorge des Schilddrüsen¬karzinoms. Nuklearmedizin 34, 87-91.
  3. Bares R, Dohmen BM, Cremerius U, Fass J, Teusch M, Bull U (1996) Ergebnisse der Positro¬nen¬emissionstomographie mit Fluor-18-markierter Fluordesoxyglukose bei Differential¬diag¬nose und Staging des Pankreaskarzinoms. Radiologe 36(5), 435-40.
  4. Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, Klever P, Sabri O, Schumpe¬lick V, Buell U (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography in the dif¬fer¬ential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24(6), 678-82.
  5. Sabri O, Schulz G, Zimny M, Schreckenberger M, Zimny D, Wagenknecht G, Kaiser HJ, Dohmen BM, Bares R, Büll U (1998) Bestimmung von Einflussgrossen fur den Therapieerfolg der Radioiodtherapie bei Patienten mit Morbus Basedow. Nuklearmedizin 37(3), 83-9.
  6. Shields AF, Grierson JR, Dohmen BM, Machulla H-J, Stayanoff JC, Lawhorn-Crews JM, Obra¬dovich BSJE, Muzik O, Manger TJ (1998) Imaging Proliferation In Vivo with [F-18]FLT and Positron Emissions Tomographie (PET). Nature Medicine 4 (11), 1334-1336
  7. Schleicher UM, Dohmen BM, Gripp St, Bares R, Büll U (1999) Knochenmarks-regeneration nach Bestrahlung der Wirbelsäule. Strahlenther Onkol 175, 374-7.
  8. Casneuf R, Uckmann F-P, Albes JM, Dohmen BM, Ziemer G (2000) A patient with five primary tumours of the aerodigestive tract and the kidney. The Interdisciplinary Tumour Board, Tubingen. Eur J Surg Oncol 26(8), 819-20
  9. Wiskirchen J, Dittmann H, Gebert R, Burgbacher B, Betsch A, Schöber W, Johst U, Dohmen BM, Kehlbach R, Rodemann HP, Bares R, Duda SH (2000) Dosis¬ab¬hän¬gige Auswirkungen des kombinierten β/γ-Emitters Rhenium-186 auf das Wachstum humaner Gefäßwandzellen. Fortschr Röntgenstr 172, 72-76.
  10. Wiskirchen J, Dittmann H, Kehlbach R, Vogle-Claussen J, Gebert R, Dohmen BM, Schöber W, Bares R, Rodemann HP, Claussen CD, Duda SH (2001) Rhenium-188 for inhibition of human aortic smooth muscle cell proliferation. Int J Radiation Oncology Biol Phys 49(3), 809-815.
  11. De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, Dohmen BM, Dittrich C, Pont J (2001) Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 19(17), 3740-4.
  12. Manz M, Riessen R, Poll L, Dohmen B, Kaiserling E, Krück W, Laniado M, Kanz L, Denzlinger C (2001) High-grade lymphoma mimicking bone crisis in Gaucher's sease. Brit J Haematol 113, 191-193.
  13. Dittmann H, Sokler M, Kollmannsberger C, Dohmen BM, Baumann C, Kopp A, Bares R, Claussen CD, Kanz L, Bokemeyer C (2001) Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep 8(6), 1393-9.
  14. Albes JM, Dohmen BM, Schott U, Schulen E, Wehrmann M, Ziemer G (2002) Value of positron emission tomography for lung cancer staging.
    Eur J Surg Oncol 28(1), 55-62.
  15. Bokemeyer C, Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Claussen CD, Bares R, Kanz L (2002) Early prediction of treatment response during high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [18F]FDG-PET. Br J Cancer 86(4), 506-1112.
  16. Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Bares R, Claussen CD, Kanz L, Bokemeyer C (2002) Prospective comparison of [18F]fluoro¬deoxy¬glucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 94(9), 2353-62.
  17. Eschmann SM, Reischl G, Bilger K, Kupferschlager J, Thelen MH, Dohmen BM, Besenfelder H, Bares R (2002) Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
    Eur J Nucl Med Mol Imaging 29(6), 760-7.
  18. Eschmann SM, Friedel G, Paulsen F, Budach W, Harer-Mouline C, Dohmen BM, Bares R (2002) FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 29(6), 804-8.
  19. Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, Bares R (2002) Early changes in [18F]FLT uptake after chemotherapy: an experimantal study. Eur J Nucl Med Mol Imaging 29(11), 1462-9.
  20. Dittmann H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, Horger M, Wehrmann M, Machulla HJ, Bares R. (2003) [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 30(10), 1407-12.
  21. Kröber SM, Marx A, Aebert H, Dohmen BM, Kaiserling E (2004) Sarcoma of folli¬cular dendritic cells in the dorsal mediastinum. Human pathology 35 (2), 259-63.
  22. De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, Kletter K, Dohmen BM, Dittrich C, Pont J (2004) 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemo¬therapy seminoma: an update of the prospective multicentric SEMPET trial.
    J Clin Oncol 22(6),1034-9.
  23. Smyczek-Gargya B, Fersis N, Dittmann H, Vogel U, Reischl G, Machulla HJ, Wallwiener D, Bares R, Dohmen BM (2004) PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study.
    Eur J Nucl Med Mol Imaging 31(5), 720-4.
  24. Krauss K, Aydeniz B, Dohmen BM, Wehrmann M, Wallwiener D, Huober J  (2004) Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 2. Detection of an appendiceal carcinoma by whole-body positron emission tomography after Caesarean section.
    J Clin Oncol 22 (14), 2966-8.
  25. Knop S, Dohmen BM, Kanz L, Bares R, Einsele H (2004) 153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma. Haematologica 89 (9), ECR36
  26. Knop S, Jakob A, Kanz L, Hebart H, Bares R, Dohmen B (2004) 186-Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 103 (3), 1175.
  27. Pfannenberg AC, Oechsle K, Kollmannsberger C, Dohmen BM, Bokemeyer C, Bares R, Vontheim R, Claussen CD (2004) Early Prediction of Treatment Response to High-Dose Chemotherapy in Patients with Relapsed Germ Cell Tumors Using [18F]FDG-PET, CT or MRI, and Tumor Marker. Röfo 176 (1), 76-84.
  28. Pfannenberg AC, Oechsle K, Bokemeyer C, Kollmannsberger C, Dohmen BM, Bares R, Hartmann JT, Vonthein R, Claussen CD (2004) The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of postchemotherapy residual masses in metastatic germ cell tumors-prospects for management.
    World J of Urol 22 (2), 132-139.
  29. Reimold M, Mueller-Schauenburg W, Becker GA, Reischl G, Dohmen BM, Bares R (2004) Non-invasive assessment of distribution volume ratios and binding potential: tissue heterogeneity and interindividually averaged time-activity curves.
    Eur J Nucl Med Mol Imaging 31 (4), 564-577.
  30. Heinz A, Reimold M, Wrase J, Hermann D, Croissant B, Mundle G, Dohmen BM, Braus DH, Schumann G, Machulla HJ, Bares R, Mann K (2005) Correlation of stable elevations in striatal {micro}-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psych 62 (1), 57-64.
  31. Wiesmann A, Einsele H, Kanz L, Dohmen BM. (2005) Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma. Bone Marrow Transplant 36(1), 89-90.  
  32. Wullner U, Reimold M, Abele M, Burk K, Minnerop M, Dohmen BM, Machulla HJ, Bares R, Klockgether T. (2005) Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch Neurol 62(8), 1280-5.
  33. Becherer A, De Santis M, Karanikas G, Szabo M, Bokemeyer C, Dohmen BM, Pont J, Dudczak R, Dittrich C, Kletter K. (2005) FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
    Eur J Radiol 54(2), 284-8.
  34. Solbach C, Patt M, Reimold M, Blocher A, Dohmen BM, Bares R, Zeller KP, Machulla HJ. (2007) [11C]Vinblastine syntheses and preliminary imaging in cancer patients. J Pharm Pharm Sci 10(2), 266s-276s.  
  35. Wit M de, Brenner W, Hartmann M, Kotzerke J, Hellwig D, Lehmann J, Franzius C, Kliesch S, Schlemmer M, Tatsch K, Heicappell R, Geworski L, Amthauer H, Dohmen BM, Schirrmeister H, Cremerius U, Bokemeyer C, Bares R (2008) [18F]-FDG–PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol 19(9),1619-23.
  36. Dittmann H, Jusufoska A, Dohmen BM, Smyczek-Gargya B, Fersis N, Pritzkow M, Kehlbach R, Vonthein R, Machulla HJ, Bares R(2009) 3'-Deoxy-3'-[(18)F]fluoro¬thymidine (FLT) uptake in breast cancer cells as a measure of proliferation after doxorubicin and docetaxel treatment. Nucl Med Biol 36(2),163-9.
  37. Boesebeck F, Schwarz O, Dohmen B, Graef U, Vestring T, Kramme C, Bien CG (2013) Faciobrachial dystonic seizures arise from cortico-subcortical abnormal brain areas. J Neurol 260(6), 1684-6

Kontakt

AGAPLESION DIAKONIEKLINIKUM ROTENBURG gemeinnützige GmbH
Nuklearmedizin und Schilddrüsendiagnostik

Elise-Averdieck-Straße 17
27356 Rotenburg (Wümme)
T (04261) 77-27 20
F (04261) 77-27 24
nuklearmedizinthis is not part of the email@ NOSPAMdiako-online.de

 

IHRE ANSPRECHPARTNERIN

Dr. med. Hilko Strehl

Dr. med. Hilko Strehl

Chefarzt

EndoProthetikZentrum

Onkologisches Zentrum